Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide.
Landon C BrownSusan HalabiJoseph D SchonhoftQian YangJun LuoDavid M NanusParaskevi GiannakakouRussell Z SzmulewitzDaniel C DanilaEthan S BarnettEmily A CarboneJimmy L ZhaoPatrick HealyMonika AnandAudrey GillAdam JendrisakWilliam L BerrySantosh GuptaSimon G GregoryRichard WenstrupEmmanuel S AntonarakisDaniel J GeorgeHoward I ScherAndrew J ArmstrongPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
A high CIN and NE CTC phenotype is independently associated with worse survival in men with mCRPC treated with abiraterone/enzalutamide, warranting further prospective controlled predictive studies to inform treatment decisions.